Year: 2019

COPENHAGEN, Denmark, December 9, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced, that its partner Janssen Pharmaceutical Companies of Johnson & Johnson will provide up to 200,000 regimens of its investigational Ebola vaccine to the Republic of Rwanda to support a new immunization program led by the Rwanda government. The vaccine regimen, which consists of the MVA-BN® Filo vaccine from Bavarian Nordic and the Ad26.ZEBOV vaccine from Janssen, will help protect the citizens of Rwanda from the current Ebola outbreak in the neighboring country, the Democratic Republic of Congo (DRC).The World Health Organization (WHO) has declared the Ebola outbreak in the DRC a Public Health Emergency of International Concern (PHEIC). More than 3,300 cases, including more than 2,200 deaths, have been reported to date, making the outbreak...

KØBENHAVN, Danmark, 9. december 2019 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag at selskabets partner Janssen, datterselskab af Johnson & Johnson, vil donere op mod 200.000 doser af deres forsøgsvaccine, mod ebola til Rwanda for at støtte et nyt immuniseringsprogram anført af Rwandas regering. Vaccinen, som består af MVA-BN® Filo-vaccinen fra Bavarian Nordic og Ad26.ZEBOV-vaccinen fra Janssen, skal beskytte landets befolkning fra det ebolaudbrud, som i øjeblikket pågår i nabolandet den Demokratiske Republik Congo (DRC).Verdenssundhedsorganisationen WHO har erklæret ebolaudbruddet i DRC en folkesundhedsmæssig krisesituation af international betydning. Til dato er mere end 3.300 tilfælde, heriblandt 2.200 dødsfald, af ebola blevet reporteret, hvilket gør udbruddet til det næststørste ebolaudbrud nogensinde. I oktober donerede...

Coop Pank aktsiaselts hereby declares that the following managers, and / or persons closely related to the person discharging managerial responsibilities, have entered into the following transactions: A notification obligation derives from the Regulation (EU) No 596/2014 of the European Parliament and of the Council article 19.Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. It has 15 branch offices and 28 banking points all over the country. The number of clients using Coop Pank for their daily banking has reached 58,300. Coop Pank aims to put the synergy generated by the interaction of retail business and banking to good use and to bring everyday banking services closer to people’s homes. The strategic shareholder of the bank is the domestic retail chain Coop Eesti comprising 330 stores. Kerli...

Coop Pank aktsiaselts (Selts) annab teada, et alljärgnevad Seltsi juhtimiskohustusi täitvad isikud ja/või juhtimiskohustusi täitvate isikute lähedased on teinud alljärgnevaid tehinguid: Teavitamiskohustus tuleneb Euroopa Parlamendi ja Nõukogu määruse (EL) nr 596/2014 artiklist 19.Eesti kapitalil põhinev Coop Pank on üks viiest Eestis tegutsevast universaalpangast. Coop Pangal on üle Eesti 15 pangakontorit ja 28 pangapunkti. Pangal on 58 300 aktiivset igapäevapanganduse klienti. Coop Pank kasutab jaekaubanduse ja panganduse vahel tekkivat sünergiat ning toob igapäevased pangateenused inimeste kodu lähedale. Panga strateegiliseks aktsionäriks on kodumaine kaubanduskett Coop Eesti, mille müügivõrgustikku kuulub 330 kauplust. Kerli LõhmusFinantsjuhtTelefon 6690902kerli.lohmus@cooppank.eewww.cooppank.ee 

Company Announcement 9 December 2019 Coop Pank’s financial results in November 2019:The bank’s customer base increased by a record 3,600, reaching 61,900 by the end of the month.In the same period, the bank’s loan portfolio increased by EUR 21 million, having reached EUR 447 million. Business loans showed the highest growth, while all other financing business lines contributed to the growth as well.The amount of deposits in Coop Pank reached EUR 507 million by the end of November, having in a month grown by EUR 12 million.The bank earned a net profit of EUR 545 thousand in November.Commentary by Margus Rink, chairman of the management board of Coop Pank: „The public offering of bank’s shares and the subscription benefit to the clients were the main drivers of customer growth in November. Secondly, we see that the best benefits of Coop...

Börsiteade 9. detsember 2019Coop Panga 2019. aasta novembri majandustulemused:Panga kliendiarv kasvas novembris rekordilise 3600 kliendi võrra ja ulatus kuu lõpuks 61 900-ni.Panga neto laenuportfell kasvas samal ajal 21 miljoni euro võrra jõudes 447 miljoni euroni. Novembris tegi suure kasvu ärilaenude portfell. Samal ajal kasvasid ka kõigi teiste äriliinide laenuportfellid.Coop Panga hoiuste maht ulatus novembri lõpu seisuga 507 miljoni euroni, kasvades kuuga 12 miljoni euro võrra.Pank teenis novembris 545 tuhat eurot puhaskasumit.Coop Panga juhatuse esimehe Margus Rinki kommentaar: „Novembri kliendiarvu kasvule andis positiivse tõuke esmalt panga aktsiate avalik pakkumine ja märkimisel antud eelis klientidele. Teiseks näeme, et alates 5. novembrist Coop Panga deebetkaardi omanikele kehtima hakanud Coopi kliendiprogrammi parimad soodustused...

Regulated informationArticle 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdingsGosselies, Belgium, 9 December 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 3 December 2019 indicating that the shareholdings held by S.R.I.W. SA (Société Régional d’Investissement de Wallonie) and its subsidiary Sofipôle SA (Société Wallonne pour le Financement des Infrastructures des Pôles de Compétitivité) have passively crossed the threshold of 10% as a result of the issuance of new shares on 14 November 2019 following the conversion of convertible bonds issued on...

Information réglementéeArticle 14, alinéa 1erde la loi du 2 mai 2007 relative à la publicité des participations importantesGosselies, Belgique, le 9 décembre 2019, 07h00 CET – BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires et biologiques innovantes répondant à d’importants besoins médicaux non satisfaits dans les domaines de l’orthopédie et des maladies osseuses, annonce aujourd’hui la réception d’une notification de transparence datée du 3 décembre 2019, dont il résulte que les positions actionnariales de S.R.I.W. SA (Société Régional d’Investissement de Wallonie) et sa filiale Sofipôle SA (Société Wallonne pour le Financement des Infrastructures des Pôles de Compétitivité) ont franchi passivement le seuil de participation de 10%...

Jörg DuschmaléBasel, 9 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting on 17 March 2020.Change in the Corporate Executive Committee Dr Gottlieb A. Keller (65), General Counsel, member of the Corporate Executive Committee, and Secretary to the Board of Directors, will retire at the end of March 2020. The Board of Directors has appointed Claudia Böckstiegel (55), currently Head of Legal of the Diagnostics Division, to the position of General Counsel, and she will become a member of the Enlarged Corporate Executive Committee as of 1 April 2020.Attachments20191209-MR-Change_BOD+CEC_ENDr Jörg DuschmaléJörg DuschmaléDr Patrick FrostPatrick FrostClaudia BöckstiegelClaudia BöckstiegelDr Annette...

Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphomaPoster presentation on data from clinical trial of BRUKINSA combined with tislelizumab in B-cell malignanciesCAMBRIDGE, Mass. and BEIJING, China, Dec. 08, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced clinical data from three trials of its BTK inhibitor BRUKINSA™ (zanubrutinib) were presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, FL. In two oral presentations of BRUKINSA in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the drug candidate...